Galectin Therapeutics Inc. (GALT)

[Tekterra]

That makes sense to me. A take over can't really happen if they aren't willing to sell. On the other hand, a partner will want ownership of the drug when commercialized. That could explain why no deals was made if management isn't willing to sell. GR-MD-02 success in the NASH market would be worth more than couple billion dollars down the road.

We don't know who's behind GALT and what those people are thinking. Last offering was a private one and I believe a billionaire was backing them with finance. Price nearly double now and we're not seeing it being sold down.

A lot of research and reports suggested that GR-MD-02 is actually better compare to other competitions out there. With it targeting late stages that can save lives will also look more favorably by FDA.

So if it's really that great, I'm sure a lot of parties would be interested. But with such a small company I find it hard for them to be able to commercialize without some sort of a partnership even if they were to hold out until approval. Transitioning from R&D to manufacturing and sales will cost a whole lot of additional funding. If this is the route management is going down, this stock won't be going anywhere for a lot longer.

People dreaming of a big partnership or a buyout would be very disappointed. This could be rewarding long term.